Press release

COVID-19: Adents’ Business Continuity plan

A MESSAGE FROM John Fitzgerald, CEO of Adents

The COVID-19 coronavirus epidemic has already affected thousands of people around the world and we expect the French government to announce stricter containment measures soon. Since Adents employees are mainly based in France and the United States, we take the health and economic risks linked to this epidemic very seriously.

With this in mind, we have already taken a series of measures to protect the health and safety of our staff and partners while anticipating the operational needs that will allow us to guarantee business continuity.

Thus, we would like to inform you of the following key points:

  • Our existing business continuity plans for both our products and our organization will be followed if needed
  • Most Adents staff members are already equipped with the necessary IT and communication tools for secure remote work if it becomes necessary due to increased risks or official containment measures
  • Business travel is restricted to critical matters. We have requested our employees to use phones and videoconferencing solutions as much as possible for all current activities with our clients, suppliers and partners
  • All our staff members are trained and familiar with necessary hygiene rules to limit the risks of contagion, as well as the procedures to be followed in the event of an identified risk of contamination

Rest assured that we are implementing all necessary measures to limit the impact of this epidemic on Adents’ activity. We are also carefully monitoring the health situation in the countries where we operate.


John Fitzgerald
CEO of Adents


Laboratoires Théa addresses European FMD and South Korea market regulation requirements with Adents Cloud serialization solution
Leading Ophtalmic Pharmaceuticals Company chose Adents Prodigi to connect with approximately 15 supply chain partners to stay compliant with current and future regulations.
Pharmascience Chooses Software from Adents to Ensure European FMD and US DSCSA Serialization Compliance Regulations
Pharmascience,the 4th largest manufacturer of over-the-counter and generic drugs in Canada, has chosen to partner with Adents, a leading provider of versatile and easily deployable serialization and track-and-trace software solutions, to assure compliance with the European Falsified Medicines Directive as well as the U.S. DSCSA serialization regulation.
VAI and Adents Partner to Offer a Complete Solution to Meet Pharmaceutical Saleable Returns Regulations
VAI, a leading ERP software developer, announced that is has partnered with Adents, the leading provider of end-to-end traceability solutions, to provide its pharmaceutical customers with a complete solution to meet upcoming requirements under the Drug Supply Chain Security Act (DSCSA).